Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3

by J.M. Piulats, E.S. Antonarakis, M. Gross-Goupil, J.C. Goh, U.N. Vaishampayan, R. De Wit, T. Alanko, S. Fukasawa, K. Tabata, S. Feyerabend, R. Berger, H. Wu, J. Kim, C. Schloss, J.S. De Bono
Published 2020-07-01

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

by R. McDermott, J.N. Graff, E.S. Antonarakis, C.J. Hoimes, S.T. Tagawa, C. Hwang, D. Kilari, A.J.T. Tije, A. Omlin, U.N. Vaishampayan, A. Elliott, H. Wu, J. Kim, C. Schloss, J.S. De Bono
Published 2020-07-01

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

by J.M. Piulats, E. Yu, G. Gravis, B. Laguerre, J. Arranz, S. Oudard, P. Fong, M. Kolinsky, M. Augustin, S. Feyerabend, A.. Kam, H. Gurney, A. Tafreshi, M. Retz, W. Berry, N. Mar, H. Wu, C. Schloss, C. Poehlein, J. De Bono
Published 2020-07-01

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castrati...

by G. Gravis, M. Kolinsky, L. Mourey, J.M. Piulats, S. Sridhar, E. Romano, W. Berry, H. Gurney, M. Retz, L. Appleman, M. Boegemann, J. De Bono, A. Joshua, U. Emmenegger, H. Conter, B. Laguerre, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Published 2020-07-01

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer...

by S. Feyerabend, W. Berry, P. Fong, J.M. Piulats, L. Appleman, H. Conter, N. Shore, G. Gravis, B. Laguerre, H. Gurney, M. Retz, E. Romano, L. Mourey, J. De Bono, A. Kam, U. Emmenegger, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Published 2020-07-01